Aura Biosciences (AURA) Non-Current Deffered Revenue (2020)
Aura Biosciences' (AURA) quarterly Non-Current Deffered Revenue came in at $8000.0 in Q4 2020.
Analysis
Aura Biosciences (AURA) Non-Current Deffered Revenue (2020) Analysis & Trends
Aura Biosciences (AURA) has 1 years of Non-Current Deffered Revenue data on file, last reported at $8000.0 in Q4 2020.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $8000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $8000.0 (changed N/A YoY) and the FY2020 annual result came in at $8000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $8000.0 in Q4 2020.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $8000.0 in Q4 2020 to a low of $8000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Aura Biosciences | 717.17 Mn | 649.33 Mn | - | - |